Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gadopiclenol vs Gadoterate Meglumine in Steno-occlusive Disease
NCT07348640Phase 3Recruiting
- Sponsor
- Guerbet
- Start
- Jul 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial of gadopiclenol in steno-occlusive disease (2 arms), sponsored by Guerbet. Primary endpoint: Diagnostic Performance Non-inferiority at 30 days. Started Jul 2026; status: recruiting.
02
Drugs
gadopiclenol
03
Conditions
steno-occlusive disease
Beyond the preview
Go deeper on NCT07348640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07348640.